This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
by Zacks Equity Research
Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View
by Zacks Equity Research
GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.
Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
by Zacks Equity Research
Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of +17.46% and +3.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Here's Why GSK (GSK) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Analyst Reports for Oracle, Toyota & Morgan Stanley
by Mark Vickery
Oracle gains from cloud momentum and AI contracts, Toyota drives hybrid and hydrogen growth, while Morgan Stanley thrives on IB strength.
GSK (GSK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why GSK (GSK) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why GSK (GSK) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Will Positive Regulatory Updates Further Boost INCY Stock?
by Zacks Equity Research
Incyte's strong 2025 performance is fueled by Jakafi's sustained growth and label expansion of Opzelura.
Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings?
by Kanishka Das
MIRM's Livmarli remains its dominant growth engine and is expected to have boosted its top line in the third quarter.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Why GSK (GSK) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy
by Zacks Equity Research
Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why GSK (GSK) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?
by Zacks Equity Research
Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.
IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal
by Zacks Equity Research
Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why GSK (GSK) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
by Zacks Equity Research
Roche is set to acquire 89bio for $3.5B, adding late-stage MASH drug pegozafermin to its cardiovascular, renal, and metabolic pipeline.
GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years
by Zacks Equity Research
GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.
LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?
by Kinjel Shah
Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.